AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
xanomeline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| cholinergic agents (muscarine receptor agonists/partial antagonists used in the treatment of Alzheimer's disease) | 3652 | 131986-45-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a cholinergic agonist; used in the treatment of Alzheimer's disease; structure given in first source
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 0.50 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.638 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.189 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 23.659 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 141.579 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 3 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 3.560 | % | High | 1 |
| herg | hERG pIC50 | 5.574 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 47.424 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 83.560 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 1.520 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,MET,NTRK2,PDK2,PDK4,PRKDC,TEK | 19 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.169 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 241.546 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 2.890 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.327 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 9.400 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 202.768 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 16.570 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 4.100 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 218.776 | uM | High | 1 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AX50 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Other antipsychotics |
| FDA MoA | N0000000104 | Cholinergic Muscarinic Agonists |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D010277 | Parasympathomimetics |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018679 | Cholinergic Agonists |
| MeSH PA | D018721 | Muscarinic Agonists |
| FDA EPC | N0000175840 | Cholinergic Muscarinic Agonist |
| FDA MoA | N0000182141 | Cytochrome P450 3A4 Inhibitors |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35941 | serotonergic agonist |
| CHEBI has role | CHEBI:38325 | muscarinic agonist |
Related Drugs by ATC class:
N05AX Other antipsychotics 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.94 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 20MG;EQ 100MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10265311 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 100MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10369143 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 100MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10369144 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 100MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10695339 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 50MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10265311 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 50MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10369143 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 50MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10369144 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 50MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10695339 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 30MG;EQ 125MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10265311 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 30MG;EQ 125MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10369143 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 30MG;EQ 125MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10369144 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 30MG;EQ 125MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10695339 | July 21, 2030 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 100MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10933020 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 100MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 11452692 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 100MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 11471413 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 100MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 11890378 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 50MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10933020 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 50MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 11452692 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 50MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 11471413 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 20MG;EQ 50MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 11890378 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 30MG;EQ 125MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 10933020 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 30MG;EQ 125MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 11452692 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 30MG;EQ 125MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 11471413 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| 30MG;EQ 125MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | 11890378 | Sept. 27, 2039 | TREATMENT OF SCHIZOPHRENIA IN ADULTS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 20MG;EQ 100MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | Sept. 26, 2029 | NEW CHEMICAL ENTITY |
| 20MG;EQ 50MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | Sept. 26, 2029 | NEW CHEMICAL ENTITY |
| 30MG;EQ 125MG BASE | COBENFY | BRISTOL-MYERS | N216158 | Sept. 26, 2024 | RX | CAPSULE | ORAL | Sept. 26, 2029 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 7.30 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 1D | GPCR | AGONIST | Ki | 8.20 | IUPHAR | ||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 5.80 | PDSP | |||||
| 5-hydroxytryptamine receptor 1F | GPCR | AGONIST | Ki | 6.50 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.10 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Ki | 6 | PDSP | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | AGONIST | Ki | 7.20 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 6.90 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2B | GPCR | ANTAGONIST | Ki | 7.70 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2C | GPCR | ANTAGONIST | Ki | 7.40 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 6 | GPCR | AGONIST | Ki | 5.90 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 7 | GPCR | AGONIST | Ki | 6.90 | IUPHAR | ||||
| D(3) dopamine receptor | GPCR | Ki | 6.40 | PDSP | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.38 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 6.92 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 7.89 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 7.14 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1E | GPCR | AGONIST | Ki | 5.60 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M2 | GPCR | IC50 | 7.80 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | IC50 | 8.70 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | EC50 | 5.24 | CHEMBL | |||||
| Muscarinic acetylcholine receptor | GPCR | IC50 | 8.01 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D06330 | KEGG_DRUG |
| 4043442 | VANDF |
| C0246836 | UMLSCUI |
| CHEBI:10056 | CHEBI |
| XNO | PDB_CHEM_ID |
| CHEMBL21536 | ChEMBL_ID |
| DB15357 | DRUGBANK_ID |
| CHEMBL2336050 | ChEMBL_ID |
| C075257 | MESH_SUPPLEMENTAL_RECORD_UI |
| 60809 | PUBCHEM_CID |
| 57 | IUPHAR_LIGAND_ID |
| 7125 | INN_ID |
| 152854-19-8 | SECONDARY_CAS_RN |
| 9ORI6L73CJ | UNII |
| 2694828 | RXNORM |
| 43212 | MMSL |
| d10222 | MMSL |
| 019865 | NDDF |
| 019868 | NDDF |
| 9ORI6L73CJ | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cobenfy | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0003-0050 | CAPSULE, COATED PELLETS | 50 mg | ORAL | NDA | 31 sections |
| Cobenfy | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0003-0125 | CAPSULE, COATED PELLETS | 125 mg | ORAL | NDA | 31 sections |
| Cobenfy | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0003-1100 | CAPSULE, COATED PELLETS | 100 mg | ORAL | NDA | 31 sections |